Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
解鎖市場時間軸與訊號動態
過去 90 日內有 17 個訊號。
此公司進入各市場的次序 — 由最舊至最新
28 active postings
Government & Reimbursement Manager
註冊以查看完整訊號動態
Masimo 的國際擴張與競爭對手的比較
Masimo你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Masimo你 | 7 | 2 | +29% | 16 | 31 |
Area Clinical Resource Manager
查看招聘Irvine, CA · 4日前
Customer Service Representative
查看招聘Irvine, CA · 上星期
Manager, OEM Product Development
查看招聘Irvine, CA · 上星期
Study Finds That When Patients Decline, Respiratory Changes Often Come First
進行中
Patient deterioration often begins with respiratory compromise
進行中
Learn how early detection of respiratory changes can support patient safety
進行中美國國際貿易委員會裁定Apple重新設計的Watch Series 9和Ultra 2不侵犯Masimo的血氧監測專利,拒絕進口禁令請求。
丹納赫報告生物加工訂單激增30%,第一季每股收益增長10%,但將呼吸產品收入預測下調1.5億美元,同時維持3-6%有機增長展望。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Masimo 業務、市場及增長訊號的快速解答。
